About Trapelo
Trapelo is a company based in Fort Myers (United States) founded in 2009 was acquired by NeoGenomics in March 2021. Trapelo has raised $16.23 million across 4 funding rounds from investors including NeoGenomics, Chrysalis Ventures and Beringea. Trapelo offers products and services including Trapelo Platform and Precision Medicine Podcast. Trapelo operates in a competitive market with competitors including Tempus, Personalis, CancerIQ, Perthera and LinkDoc, among others.
- Headquarter Fort Myers, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.23 M (USD)
in 4 rounds
-
Latest Funding Round
$4.16 M (USD), Series B
Nov 08, 2017
-
Investors
NeoGenomics
& 4 more
-
Employee Count
Not available
-
Acquired by
NeoGenomics
(Mar 24, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Trapelo
Trapelo offers a comprehensive portfolio of products and services, including Trapelo Platform and Precision Medicine Podcast.
Platform for precision medicine testing and treatment decisions.
Podcast featuring discussions on precision medicine innovations.
People of Trapelo
Unlock access to complete
Unlock access to complete
Funding Insights of Trapelo
Trapelo has successfully raised a total of $16.23M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $4.16 million completed in November 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Trapelo
Trapelo has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include NeoGenomics, Chrysalis Ventures and Beringea.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
VC firm making investment in early & growth stage healthcare & tech companies in the US
|
Locked | Locked | Locked | |
|
Investments are made in growth-stage startups by Beringea.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Trapelo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Trapelo
Investment portfolio details for Trapelo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Trapelo
Detailed financials for Trapelo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Trapelo Comparisons
Peer comparison for Trapelo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Trapelo
Trapelo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tempus, Personalis, CancerIQ, Perthera and LinkDoc, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based precision medicine solutions for oncology are provided.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
CancerIQ is focused on precision cancer prevention and care.
|
|
| Locked | Locked | Locked |
Molecular cancer profiling is conducted via genomics and proteomics.
|
|
| Locked | Locked | Locked |
Oncology-focused database is provided for cancer analytics.
|
Detailed competitors of Trapelo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Trapelo
Complete news archive for Trapelo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Trapelo
Trapelo was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Trapelo is headquartered in Fort Myers, United States. It is registered at Fort Myers, Florida, United States.
Trapelo is a funded company, having raised a total of $16.23M across 4 funding rounds to date.
Trapelo was founded in 2009 and is headquartered in Fort Myers, United States. The company operates in the healthcare sector, focusing on oncology through a unified technology platform. Real-time evidence-based decision support is enabled, along with treatment selection and reimbursement assurance for oncologists. The platform is utilized by providers, payers, pathologists, and related stakeholders to facilitate precision medicine applications.
Trapelo's top competitors include Tempus, Personalis and CancerIQ.
Trapelo offers Trapelo Platform and Precision Medicine Podcast.
Trapelo has 5 investors. Key investors include NeoGenomics, Chrysalis Ventures, Beringea, Hopen Life Science Ventures, and Charter Capital Partners.